DailyIQ
|
Sector:HealthcareAll sectors
Last updated 14 hours ago

RPRX·Royalty Pharma plc

$.
-. (-.%)
After Hours
High
$59.95
Open
$59.56
Market Cap
33.88B
52W High
$59.72
Low
$58.51
P. Close
$58.81
P/E
40.95
52W Low
$34.08
Fwd P/E
10.52
DailyIQ Est.
$62.11
Technical Score (1D)
95
BUY
News Sentiment
-
NO DATA
Royalty Pharma’s board approved a $0.235 per share dividend for Q3 2026, to be paid on September 10 2026 to shareholders of record as of August 14 2026, reinforcing the company’s strategy of generating returns from its extensive royalty portfolio. The dividend announcement signals continued confidence in the company’s royalty‑based business model and its ability to sustain cash flow, which could support the stock’s valuation over the next 1–10 trading days. TD Cowen has upgraded Royalty Pharma to a Buy rating and raised its price target from $50 to $65, reflecting optimism about the company’s steady cash flow prospects. This upgrade may buoy investor sentiment and could lead to a modest rally as traders anticipate the next earnings announcement and any new royalty agreements that could further strengthen cash flow. Earlier today, RPRX shares hit a new intraday high, indicating strong market enthusiasm for the company’s royalty portfolio and potential future earnings. The high suggests that investors are already pricing in the dividend and the upgraded target, but the rally could be tempered if forthcoming guidance fails to confirm the bullish outlook. An insider sale of $8.16 million in shares was reported, a moderate divestment that could signal a shift in confidence but is not a large‑scale sell‑off. While the insider sale may introduce short‑term volatility, it is unlikely to alter the long‑term valuation trajectory, though traders should monitor the next earnings release for context. The combination of dividend, rating upgrade, intraday high, and insider activity creates a complex environment where the next earnings guidance will be the key watch item to confirm or temper the bullish sentiment.
Earnings Summary
Royalty Pharma is a New York‑based investment firm that specializes in acquiring royalty interests in biopharmaceutical products, providing funding for innovative therapies across oncology, rare diseases, and infectious diseases. In the last two quarters, the company posted a 17.6% revenue increase from $742 million in Q4 2024 to $874 million in Q4 2025, followed by a 5.7% rise to $925 million in Q1 2026, indicating a deceleration in growth acceleration. EPS also trended upward, beating estimates in each period: $1.1511 versus $1.05403 in Q4 2024, $1.46 versus $1.15 in Q4 2025, and $1.30 versus $1.2368 in Q1 2026, underscoring consistent earnings strength. Historically, Royalty Pharma has maintained a steady YoY revenue trajectory with each quarter surpassing analyst expectations, and its royalty‑based model has delivered EPS beats even as revenue growth moderates. Recent news highlights a $0.235 per share dividend for Q3 2026, a TD Cowen buy rating upgrade with a target rise to $65, and an intraday high driven by investor enthusiasm; these developments reinforce confidence in the company’s cash‑flow generation and may support valuation momentum, though insider sales suggest short‑term volatility. Investors should watch the forthcoming Q2 2026 earnings release for guidance on revenue and EPS, the sustainability of the dividend payout, and any new royalty agreements that could confirm or temper the bullish sentiment, while monitoring the impact of the dividend on liquidity and the potential for further rating adjustments.

EPS

EstBeatMiss
$0.99$1.13$1.26$1.39$1.52Q4'24Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$1.27 - -
Q1'26$1.24$1.30+5.1%
Q4'25$1.15$1.46+27.0%
Q4'24$1.05$1.15+9.2%

Revenue

EstBeatMiss
$624M$804M$983M$1.2B$1.3BQ4'24Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$707M - -
Q1'26$1.3B$925M-26.6%
Q4'25$859M$874M+1.7%
Q4'24 - $742M -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

RPRX Stock Snapshot

RPRX is currently trading at $59.66, giving Royalty Pharma plc a market cap of 33.88B and a P/E ratio of 41.0. Today's range spans $58.51–$59.95, with shares opening at $59.56 and moving up $0.85 (1.4%) from the prior close. DailyIQ's technical score sits at 95/100 (BUY).

Over the past year RPRX has traded between $34.08 and $59.72 - the current price is +75.1% off the 52-week low and -0.1% from the high. 18 analysts cover the stock with a Buy consensus and a mean 12-month target of $59.89 (range $46.00–$66.00), implying upside of +0.4%.

Dividend-paying Healthcare stocks at the large-cap level tend to attract a different buyer mix than pure growth names - and RPRX (33.88B market cap) with a BUY read (95/100) and neutral sentiment (-/100) benefits from both income-oriented and growth-oriented flows. The current P/E ratio stands at 41.0. Price: $59.66 (near 52-week highs in $34.08–$59.72). When technical momentum aligns with that dual-buyer base, the price path tends to be more durable than single-buyer-type momentum trades.

Earnings revision cycles in large-cap Healthcare names tend to compound: when technicals confirm a BUY thesis (95/100) and news sentiment (-/100, neutral) supports the narrative, analyst upgrades follow price rather than lead it. At $59.66 (near 52-week highs), RPRX's position within the $34.08–$59.72 annual range suggests there's room for multiple expansion before the stock encounters meaningful technical resistance.